SCHEMBL20122752

SCHEMBL20122752

Cc1nccc2c1[nH]c1c(-c3ccc(OCc4ncc5ccccc5n4)cc3)cc(Cl)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 5/20 0.43
MAOA P21397 10/20 0.43
DYRK1A Q13627 2/20 0.39
CYSLTR1 Q9Y271 1/20 0.39
ALOX5AP P20292 1/20 0.39
KDM4E B2RXH2 1/20 0.35
DYRK3 O43781 1/20 0.35
CCNT1 O60563 1/20 0.35
CCNB2 O95067 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CDK1 P06493 1/20 0.35
CYP3A4 P08684 1/20 0.35
ADRA2A P08913 1/20 0.35
CYP2D6 P10635 1/20 0.35
CCNB1 P14635 1/20 0.35
HPGD P15428 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
CCNA2 P20248 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664231 0.91 MAOA (0.42) PDE10AMAOADYRK1ACYSLTR1KDM4E
SCHEMBL20123070 0.91 MAOA (0.42) PDE10AMAOADYRK1ACYSLTR1KDM4E
SCHEMBL20123078 0.88 MAOA (0.46) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL30664311 0.88 MAOA (0.46) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL20122931 0.86 PDE10A (0.52) PDE10AALOX5AP
SCHEMBL29756400 0.86 PDE10A (0.52) PDE10AALOX5AP
SCHEMBL30664225 0.83 MAOA (0.60) MAOADYRK1AGSK3B
SCHEMBL20123024 0.83 MAOA (0.60) MAOADYRK1AGSK3B
SCHEMBL20123020 0.83 MAOA (0.45) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL30664156 0.83 MAOA (0.45) MAOADYRK1AKDM4EDYRK3CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 PDE10A 415/4885MAOA 245/4885DYRK1A 493/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 PDE10A 415/4885MAOA 245/4885DYRK1A 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.